Julie Gould

Articles by Julie Gould

Julie GouldMyelodysplastic Syndromes | October 28, 2024
A novel multivariate model improved risk stratification in MDS compared with both the IPSS-R and IPSS-M.
Julie GouldMyelodysplastic Syndromes | October 28, 2024
The rate of abnormal cytogenetics among AA patients with MDS is comparable to or lower than the general population.
Julie GouldMyelodysplastic Syndromes | October 28, 2024
CDC database analysis suggests that MDS-related mortality has declined since 2011, though significant disparities remain.
Julie GouldMyelodysplastic Syndromes | October 28, 2024
The COMMANDS study compared the efficacy of luspatercept with epoetin alfa in ESA-naïve lower-risk MDS.
Julie GouldMyeloma | October 1, 2024
MRD negativity is a strong predictor of better prognosis and survival in patients with MM.
Julie GouldMyeloma | October 1, 2024
Ongoing detection of TP53 mutations remains critical for accurate risk stratification and treatment planning in MM.
Julie GouldMyeloma | October 1, 2024
Patients with double-hit or triple-hit MM had significantly poorer outcomes compared to those with single-hit MM.
Julie GouldMyeloma | October 1, 2024
Novel agents such as belantamab mafodotin may improve PFS in patients with relapsed MM after anti-CD38 treatment.
Julie GouldMyelofibrosis | September 9, 2024
The phase III MANIFEST-2 trial compared pelabresib plus ruxolitinib with placebo plus ruxolitinib in JAKi-naive patients.
Julie GouldMyelofibrosis | September 6, 2024
The findings were from a retrospective study of patient data from the US Flatiron Health electronic health record database.
Julie GouldMyelofibrosis | September 9, 2024
A retrospective analysis covered two phase III trials of the JAK2 inhibitor in patients with and without monocytosis.
Julie GouldMyelofibrosis | September 6, 2024
A study evaluated progression according to hemoglobin levels, platelet counts, constitutional symptoms, and other markers.